Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04898634 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
A Phase 1 study of Prostatic Neoplasms, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
- 17
- Study locations
NCT04898634 is a Phase 1 study of Prostatic Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 216 participants, below the 511-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (58% lower). The trial reports 17 study locations across 3 states.
The verdict
NCT04898634, a Phase 1 study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Conditions Studied
Interventions
- DRUG JNJ-78278343
Study Locations (17)
Other
- Peking University Third Hospital - Beijing
- Chongqing University Cancer Hospital - Chongqing
- Sun Yat Sen University Cancer Center - Guangzhou
- First Affiliated Hospital Of Wenzhou Medical College - Wenzhou
- Centre Leon Berard - Lyon
- APHM Hopital Timone - Marseille
- Institut Gustave Roussy - Villejuif
- National Cancer Center Hospital East - Kashiwa
- Yokohama City University Medical Center - Yokohama
- Antoni van Leeuwenhoek - Amsterdam
- Erasmus MC - Rotterdam
- Hosp Univ Fund Jimenez Diaz - Madrid
- Hosp Univ Hm Sanchinarro - Madrid
- Hosp Virgen de La Victoria - Málaga
New York
- Columbia University Medical Center Herbert Irving Pavilion - New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2027-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04898634
The ClinicalTrials.gov registry entry for NCT04898634 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 511-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (58% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JNJ-78278343 is the first listed.
NCT04898634 reports 17 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT04898634 about?
NCT04898634 is a clinical study titled "A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer". The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
What is the current status of trial NCT04898634?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2021-07-13. Estimated completion is 2027-02-10.
What conditions does trial NCT04898634 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT04898634?
The interventions under investigation include: JNJ-78278343 (DRUG).
Who is sponsoring clinical trial NCT04898634?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04898634 being conducted?
This trial has 17 study locations across New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
RECRUITING · Phase 1
-
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
RECRUITING · Phase 1
-
A Study of DM002 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.